ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA accepts Sarepta’s NDA for precision medicine Golodirsen pharmaceutical-technology
February 18, 2019US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug Golodirsen (SRP-4053)....
Pharma Sources Insight January 2025
